Key Highlights:
- Harrow Inc. partners with Nordic Pharma to launch a generic version of Maxitrol, boosting shares by 3.8%.
- Analysts reveal a promising average 1-year price target for Harrow, projecting significant upside potential.
- Harrow Inc. receives an "Outperform" brokerage recommendation, indicating a strong market position.
Harrow Inc. (HROW, Financial) has strategically collaborated with Nordic Pharma to bring a generic alternative of Maxitrol to the market. Originally developed by Novartis, this product targets bacterial eye infections. The news of this partnership has positively impacted Harrow's stock, with shares rising by 3.8% in afternoon trading.
Wall Street Analysts' Forecast for Harrow Inc.
Wall Street analysts have set a one-year average price target for Harrow Inc. (HROW, Financial) at $57.44. This projection includes a high estimate of $65.00 and a low of $52.20, indicating a potential upside of 128.98% from the current stock price of $25.09. Investors seeking detailed forecast data can explore the Harrow Inc. (HROW) Forecast page.
The consensus from 5 leading brokerage firms rates Harrow Inc. (HROW, Financial) at 1.8, classifying it as "Outperform." The rating scale, ranging from 1 to 5, assigns 1 as "Strong Buy" and 5 as "Sell," showcasing the stock's favorable position in the market.
Per GuruFocus estimates, the GF Value of Harrow Inc. (HROW, Financial) for the upcoming year is projected at $37.34. This value suggests an upside of 48.85% from its current price of $25.085. The GF Value reflects GuruFocus' assessment of the stock's fair trading value, determined through historical trading multiples, past business growth, and anticipated future performance. For an in-depth analysis, visit the Harrow Inc. (HROW) Summary page.
